Colesevelam
- Generic Name
- Colesevelam
- Brand Names
- Cholestagel, Lodalis, Welchol
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 182815-43-6
- Unique Ingredient Identifier
- 1XU104G55N
- Background
Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps ...
- Indication
用于以胆固醇升高为主的高脂血症，当饮食和锻炼不能良好达到效果者，可单独使用或与他汀类合用。
- Associated Conditions
- Heterozygous Familial Hypercholesterolemia (HeFH), Hyperlipidemias, Type 2 Diabetes Mellitus, Primary Hyperlipidemia
- Associated Therapies
- -
The Role of Metformin and Colesevelam in Human GLP-1 Secretion
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 12
- Registration Number
- NCT02050074
- Locations
- 🇩🇰
Diabetes Research Division, Department of Medicine, Gentofte Hospital, Hellerup, Copenhagen, Denmark
Effects of Fish Oil and Colesevelam (STAIR7007)
- Conditions
- Interventions
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 13
- Registration Number
- NCT01948648
- Locations
- 🇨🇦
Richardson Center for Functional Foods and Nutraceuticals, Winnipeg, Manitoba, Canada
Effect of Bile Acids on GLP-1 Secretion
- Conditions
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 20
- Registration Number
- NCT01666223
- Locations
- 🇩🇰
Diabetes Research Division, Department of Internal Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Copenhagen, Denmark
The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion
- Conditions
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Filip Krag Knop
- Target Recruit Count
- 10
- Registration Number
- NCT01656057
- Locations
- 🇩🇰
University Hospital of Copenhagen, Gentofte Hospital, Diabetic Research Division, Copenhagen, Hellerup, Denmark
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2012-01-06
- Lead Sponsor
- Radiant Research
- Target Recruit Count
- 140
- Registration Number
- NCT01239004
- Locations
- 🇺🇸
Radiant Research, Chicago, Illinois, United States
Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- Florian Beigel
- Target Recruit Count
- 34
- Registration Number
- NCT01203254
- Locations
- 🇩🇪
Praxis Dr. Mroß, Berlin, Germany
🇩🇪Hochschulambulanz Med. Klinik I - Charite-, Berlin, Germany
🇩🇪Hamburgisches Forschungsinstitut für CED, Hamburg, Germany
Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
- Conditions
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2012-11-21
- Target Recruit Count
- 21
- Registration Number
- NCT00990184
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 38
- Registration Number
- NCT00951899
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?
- Conditions
- Interventions
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2012-04-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 24
- Registration Number
- NCT00911612
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Welchol as Monotherapy for Type 2 Diabetes Mellitus
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 357
- Registration Number
- NCT00789737
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.